Cart
sales@molnova.com
Kras4B G12D-IN-1
CAS No. 2042365-85-3
Kras4B G12D-IN-1( —— )
Catalog No. M37146 CAS No. 2042365-85-3
Kras4B G12D-IN-1 is an anticancer agent that functions as an inhibitor of the Kras4B G12D protein. It effectively reduces the expression of Kras protein in mouse embryonic fibroblasts (MEFs) harboring the Kras4B G12D mutation.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 147 | In Stock |
|
| 10MG | 242 | In Stock |
|
| 25MG | 477 | In Stock |
|
| 50MG | 762 | In Stock |
|
| 100MG | 1134 | In Stock |
|
| 500MG | 2277 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameKras4B G12D-IN-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionKras4B G12D-IN-1 is an anticancer agent that functions as an inhibitor of the Kras4B G12D protein. It effectively reduces the expression of Kras protein in mouse embryonic fibroblasts (MEFs) harboring the Kras4B G12D mutation.
-
DescriptionKras4B G12D-IN-1 is a Kras4B G12D inhibitor with anticancer effects. Kras4B G12D-IN-1 decreases Kras protein expression in mouse embryonic fibroblasts (MEF) expressing Kras4B G12D (WO2016179558A1, Comp 994566).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorKras
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2042365-85-3
-
Formula Weight372.87
-
Molecular FormulaC16H21ClN2O4S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (268.19 mM; Ultrasonic )
-
SMILESC(=O)(C1=C(OC)C=CC(Cl)=C1)N2C[C@@H](CNS(C=C)(=O)=O)CCC2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Frank Mccormick, et al. K-ras modulators. WO2016179558A .
molnova catalog
related products
-
Melliferone
Melliferone is a natural product from Fructus Lipuidambaris Liquidambar taiwaniana Hance.
-
Coluracetam
A nootropic agent that enhances high-affinity choline uptake.
-
Ecliptasaponin A
Ecliptasaponin A has protective effects against the pulmonary fibrosis induced by bleomycin via reducing the oxidative stress, lung tissue inflammation, and the subsequent epithelial-mesenchymal transition.
